Estimating explainable Alzheimer's disease likelihood map via clinically-guided prototype learning

Neuroimage. 2023 Jun:273:120073. doi: 10.1016/j.neuroimage.2023.120073. Epub 2023 Apr 8.

Abstract

Identifying Alzheimer's disease (AD) involves a deliberate diagnostic process owing to its innate traits of irreversibility with subtle and gradual progression. These characteristics make AD biomarker identification from structural brain imaging (e.g., structural MRI) scans quite challenging. Using clinically-guided prototype learning, we propose a novel deep-learning approach through eXplainable AD Likelihood Map Estimation (XADLiME) for AD progression modeling over 3D sMRIs. Specifically, we establish a set of topologically-aware prototypes onto the clusters of latent clinical features, uncovering an AD spectrum manifold. Considering this pseudo map as an enriched reference, we employ an estimating network to approximate the AD likelihood map over a 3D sMRI scan. Additionally, we promote the explainability of such a likelihood map by revealing a comprehensible overview from clinical and morphological perspectives. During the inference, this estimated likelihood map served as a substitute for unseen sMRI scans for effectively conducting the downstream task while providing thorough explainable states.

Keywords: Alzheimer’s Disease; Explainable AI; Prototype Learning.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / diagnostic imaging
  • Biomarkers
  • Brain / diagnostic imaging
  • Cognitive Dysfunction*
  • Humans
  • Learning
  • Magnetic Resonance Imaging / methods
  • Neuroimaging / methods

Substances

  • Biomarkers